<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Before and after intravenous administration of 1-1.5 mg nimotop 18 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> underwent EEG, integral body rheography, computed tomography and measurement of regional volumetric cerebral circulation (RVCC) </plain></SENT>
<SENT sid="1" pm="."><plain>Nimotop appeared to increase RVCC in the infarction zone, especially in low initial RVCC levels </plain></SENT>
<SENT sid="2" pm="."><plain>The drug induced a shift to EEG normalization and a hypotensive effect, cerebral hemodynamics remaining without changes </plain></SENT>
<SENT sid="3" pm="."><plain>Nimodipine-type calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> favourably affect brain perfusion and bioelectric activity which is promising for application in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
</text></document>